(RFL) Rafael Holdings - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75062E1064
RFL: Cancer, Drugs, Real, Estate
Rafael Holdings, Inc. (NYSE:RFL) is a holding company with diversified interests in clinical-stage pharmaceuticals and commercial real estate across the United States and Israel. The company operates through three primary segments: Healthcare, Infusion Technology, and Real Estate. Its healthcare division focuses on therapies targeting metabolic differences between cancer and normal cells. The lead drug candidate, CPI-613 (devimistat), is in Phase 2 trials for advanced solid cancers, including colorectal and pancreatic cancers, in combination with existing chemotherapies. Additional pipeline assets include Promitil, a mitomycin-C prodrug, and Promi-Dox, a dual-drug liposome for various tumors.
The company also develops surgical devices, such as orthopedic arthroscopy instruments for Carpal Tunnel syndrome. Real estate holdings provide diversification and cash flow stability. Incorporated in 2017 and headquartered in Newark, New Jersey, Rafael Holdings trades on the NYSE with a market capitalization of approximately $50.53 million. Its stock has shown recent price weakness, trading below its 20-day and 50-day moving averages.
Additional Sources for RFL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RFL Stock Overview
Market Cap in USD | 46m |
Sector | Real Estate |
Industry | Real Estate Services |
GiC Sub-Industry | Real Estate Development |
IPO / Inception | 2018-03-26 |
RFL Stock Ratings
Growth 5y | -54.4% |
Fundamental | -64.8% |
Dividend | 0.0% |
Rel. Strength Industry | -3.15 |
Analysts | - |
Fair Price Momentum | 1.37 USD |
Fair Price DCF | - |
RFL Dividends
No Dividends PaidRFL Growth Ratios
Growth Correlation 3m | 24% |
Growth Correlation 12m | 64.1% |
Growth Correlation 5y | -81.5% |
CAGR 5y | -30.72% |
CAGR/Max DD 5y | -0.31 |
Sharpe Ratio 12m | -0.09 |
Alpha | -0.44 |
Beta | 0.41 |
Volatility | 54.74% |
Current Volume | 15k |
Average Volume 20d | 19.5k |
As of March 17, 2025, the stock is trading at USD 1.83 with a total of 15,019 shares traded.
Over the past week, the price has changed by -2.92%, over one month by -12.02%, over three months by -3.43% and over the past year by +6.40%.
No, based on ValueRay Fundamental Analyses, Rafael Holdings (NYSE:RFL) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -64.76 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RFL as of March 2025 is 1.37. This means that RFL is currently overvalued and has a potential downside of -25.14%.
Rafael Holdings has no consensus analysts rating.
According to ValueRays Forecast Model, RFL Rafael Holdings will be worth about 1.5 in March 2026. The stock is currently trading at 1.83. This means that the stock has a potential downside of -19.13%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 1.5 | -19.1% |